Yung-Chi Cheng
Overview
Explore the profile of Yung-Chi Cheng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
180
Citations
2851
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verma N, Johung K, Kortmansky J, Zaheer W, Lacy J, Cecchini M, et al.
J Gastrointest Oncol
. 2024 Jul;
15(3):1050-1059.
PMID: 38989411
Background: Pre-operative chemoradiation for rectal cancer is often associated with severe gastrointestinal (GI) toxicity which can interrupt, delay, and/or lead to termination of treatment. In this study, we evaluated whether...
2.
Chen H, Chen C, Hsieh W, Huang Y, Hsu T, Tsai F, et al.
Sci Rep
. 2024 Jun;
14(1):14330.
PMID: 38906945
This study aimed to investigate the association between obesity and herpes zoster (HZ) occurrence. This study used data covering 2 million people in Taiwan in 2000, which were obtained from...
3.
Gratton J, Lin M, Yu J, Weiss E, Jiang Z, Fairchild T, et al.
Cancer Cell
. 2024 May;
42(6):1127.
PMID: 38821059
No abstract available.
4.
Yu C, Chen C, Cheng Y, Hsieh W, Hsu T, Tsai F, et al.
Eur J Med Res
. 2023 Dec;
28(1):550.
PMID: 38042817
Background: Disease-related stress can trigger the occurrence of herpes zoster (HZ). Fatty liver disease (FLD) can have adverse effects on the human body and may induce stress in affected individuals....
5.
Lam W, Arammash M, Cai W, Guan F, Jiang Z, Liu S, et al.
Front Pharmacol
. 2023 Oct;
14:1244655.
PMID: 37860121
Prostate cancer is the second leading cause of cancer death among men in the United States. Castration-Resistant Prostate Cancer (CRPC) often develops resistance to androgen deprivation therapy. Resistance in CRPC...
6.
Zhong H, Wang W, Zhou W, Liang J, Cheng Y, Ma D, et al.
Genes Dis
. 2023 Jul;
10(5):1735-1738.
PMID: 37492738
No abstract available.
7.
Chen S, Li Z, Xu J, Ding M, Shan Y, Cheng Y, et al.
Acta Pharmacol Sin
. 2023 Mar;
44(8):1637-1648.
PMID: 36882503
Hepatitis C virus (HCV) infection is one of the major factors to trigger a sustained hepatic inflammatory response and hence hepatocellular carcinoma (HCC), but direct-acting-antiviral (DAAs) was not efficient to...
8.
Li K, Yu X, Maskey A, Musa I, Wang Z, Garcia V, et al.
Front Pharmacol
. 2023 Feb;
13:1042756.
PMID: 36793921
Cytochrome P450 (CYP) 3A4 is a major drug metabolizing enzyme for corticosteroids (CS). Epimedium has been used for asthma and variety of inflammatory conditions with or without CS. It is...
9.
Wang C, Chen C, Hsieh W, Hsu T, Hsu C, Cheng Y, et al.
Int J Environ Res Public Health
. 2023 Feb;
20(3).
PMID: 36768020
Background: Pulmonary tuberculosis (TB), a global health problem, is typically caused by the bacterium . Herpes zoster (HZ) is caused by the reactivation of the varicella-zoster virus (VZV). The reactivation...
10.
Lam W, Hu R, Liu S, Cheng P, Cheng Y
Front Pharmacol
. 2023 Jan;
13:1095186.
PMID: 36686648
YIV-906 is a systems biology botanical cancer drug, inspired by a traditional Chinese herbal formulation. Results from eight Phase I/II to II clinical studies demonstrated the potential of YIV-906 to...